AVAX Technologies, Inc. (AVXT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Philadelphia, PA, 미국. 현재 CEO는 Adele Sommerfeld.
AVXT 을(를) 보유 IPO 날짜 1997-05-15, 9 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $6.89K.
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
